56.60 0.00 (0.00%)
After hours: 4:58PM EDT
|Bid||56.49 x 800|
|Ask||59.88 x 800|
|Day's Range||56.31 - 57.67|
|52 Week Range||50.60 - 97.38|
|Beta (3Y Monthly)||1.03|
|PE Ratio (TTM)||47.97|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Neogen Corp NASDAQ/NGS:NEOGView full report here! Summary * Bearish sentiment is moderate and increasing Bearish sentimentShort interest | NeutralShort interest is moderate for NEOG with between 5 and 10% of shares outstanding currently on loan. This represents an increase in short interest as investors who seek to profit from falling equity prices added to their short positions on May 1. Money flowETF/Index ownership | NeutralETF activity is neutral. The net inflows of $2.39 billion over the last one-month into ETFs that hold NEOG are not among the highest of the last year and have been slowing. Economic sentimentPMI by IHS Markit | NeutralAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Consumer Goods sector is rising. The rate of growth is weak relative to the trend shown over the past year, however. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to firstname.lastname@example.org.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! We've lost count of how many times insiders have accumulated shares in a company that goes on to improve...
Does Neogen Corporation (NASDAQ:NEOG) represent a good buying opportunity at the moment? Let’s briefly check the hedge fund interest towards the company. Hedge fund firms constantly search out bright intellectuals and highly-experienced employees and throw away millions of dollars on satellite photos and other research activities, so it is no wonder why they tend to […]
Many investors are still learning about the various metrics that can be useful when analysing a stock. This article is for those who would like to learn about Return On Equity (ROE). To keep the lesson grounded in practicality, we...
Continued weakness in the global animal protein market and strongly negative currency conversions posed as headwinds for Neogen (NEOG) in third-quarter fiscal 2019.
tumbled Tuesday after the food-safety and animal sciences company released disappointing quarterly earnings. The Lansing, Michigan-based company was trading down 9.1% to $55.06 as both net earnings for the fiscal third quarter and earnings per share slid. "The quarterly results we are reporting today reflect a number of challenges in the quarter, including continued weakness in the global animal protein market and currency translation headwinds," said John Adent, Neogen's president and chief executive, in a press statement.
The Lansing, Michigan-based company said it had profit of 25 cents per share. The results missed Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research was ...
Neogen (NEOG) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Neogen Corporation (NASDAQ:NEOG), which is in the medical equipment business, and is based in United States, saw a double-digit share price rise of over 10% in the past couple ofRead More...
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! The goal of this article is to Read More...
Neogen's (NEOG) genomic business shows steady growth on acquisitions in Australia and Brazil. Stiff rivalry a cause of concern.